BEAM THERAPEUTICS INC (BEAM) Fundamental Analysis & Valuation

NASDAQ:BEAM • US07373V1052

25.16 USD
-0.43 (-1.68%)
At close: Mar 13, 2026
24.9002 USD
-0.26 (-1.03%)
After Hours: 3/13/2026, 8:11:19 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This BEAM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

BEAM gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 519 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for BEAM as it has an excellent financial health rating, but there are worries on the profitability. BEAM shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

2

1. BEAM Profitability Analysis

1.1 Basic Checks

  • BEAM had negative earnings in the past year.
  • In the past year BEAM has reported a negative cash flow from operations.
  • BEAM had negative earnings in each of the past 5 years.
  • In the past 5 years BEAM reported 4 times negative operating cash flow.
BEAM Yearly Net Income VS EBIT VS OCF VS FCFBEAM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100M -200M -300M -400M

1.2 Ratios

  • BEAM's Return On Assets of -5.40% is amongst the best of the industry. BEAM outperforms 85.36% of its industry peers.
  • BEAM has a better Return On Equity (-6.46%) than 89.02% of its industry peers.
Industry RankSector Rank
ROA -5.4%
ROE -6.46%
ROIC N/A
ROA(3y)-16.2%
ROA(5y)-19.06%
ROE(3y)-23.77%
ROE(5y)-31.11%
ROIC(3y)N/A
ROIC(5y)N/A
BEAM Yearly ROA, ROE, ROICBEAM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 -400

1.3 Margins

  • BEAM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BEAM Yearly Profit, Operating, Gross MarginsBEAM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200K -400K -600K -800K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. BEAM Health Analysis

2.1 Basic Checks

  • BEAM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, BEAM has more shares outstanding
  • BEAM has more shares outstanding than it did 5 years ago.
  • BEAM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BEAM Yearly Shares OutstandingBEAM Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
BEAM Yearly Total Debt VS Total AssetsBEAM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B

2.2 Solvency

  • BEAM has an Altman-Z score of 5.08. This indicates that BEAM is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 5.08, BEAM is in the better half of the industry, outperforming 73.03% of the companies in the same industry.
  • There is no outstanding debt for BEAM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.08
ROIC/WACCN/A
WACC8.91%
BEAM Yearly LT Debt VS Equity VS FCFBEAM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B

2.3 Liquidity

  • BEAM has a Current Ratio of 13.09. This indicates that BEAM is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 13.09, BEAM belongs to the top of the industry, outperforming 88.25% of the companies in the same industry.
  • A Quick Ratio of 13.09 indicates that BEAM has no problem at all paying its short term obligations.
  • BEAM has a better Quick ratio (13.09) than 88.25% of its industry peers.
Industry RankSector Rank
Current Ratio 13.09
Quick Ratio 13.09
BEAM Yearly Current Assets VS Current LiabilitesBEAM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. BEAM Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 24.83% over the past year.
  • BEAM shows a strong growth in Revenue. In the last year, the Revenue has grown by 120.01%.
  • The Revenue has been growing by 487.30% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)24.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.55%
Revenue 1Y (TTM)120.01%
Revenue growth 3Y31.88%
Revenue growth 5Y487.3%
Sales Q2Q%279.52%

3.2 Future

  • The Earnings Per Share is expected to grow by 8.59% on average over the next years. This is quite good.
  • Based on estimates for the next years, BEAM will show a very strong growth in Revenue. The Revenue will grow by 83.72% on average per year.
EPS Next Y-35.55%
EPS Next 2Y-17.14%
EPS Next 3Y-8.39%
EPS Next 5Y8.59%
Revenue Next Year23.62%
Revenue Next 2Y29.57%
Revenue Next 3Y51.98%
Revenue Next 5Y83.72%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
BEAM Yearly Revenue VS EstimatesBEAM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
BEAM Yearly EPS VS EstimatesBEAM Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. BEAM Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BEAM. In the last year negative earnings were reported.
  • Also next year BEAM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BEAM Price Earnings VS Forward Price EarningsBEAM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BEAM Per share dataBEAM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • BEAM's earnings are expected to decrease with -8.39% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17.14%
EPS Next 3Y-8.39%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BEAM Dividend Analysis

5.1 Amount

  • No dividends for BEAM!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BEAM Fundamentals: All Metrics, Ratios and Statistics

BEAM THERAPEUTICS INC

NASDAQ:BEAM (3/13/2026, 8:11:19 PM)

After market: 24.9002 -0.26 (-1.03%)

25.16

-0.43 (-1.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-24
Earnings (Next)05-04
Inst Owners104.64%
Inst Owner Change2.77%
Ins Owners1.17%
Ins Owner Change-1.56%
Market Cap2.56B
Revenue(TTM)139.74M
Net Income(TTM)-79.99M
Analysts86.4
Price Target49.1 (95.15%)
Short Float %20.18%
Short Ratio11.1
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)43.05%
Min EPS beat(2)-3.72%
Max EPS beat(2)89.82%
EPS beat(4)2
Avg EPS beat(4)24.25%
Min EPS beat(4)-3.72%
Max EPS beat(4)89.82%
EPS beat(8)6
Avg EPS beat(8)16.1%
EPS beat(12)10
Avg EPS beat(12)36.44%
EPS beat(16)13
Avg EPS beat(16)32.07%
Revenue beat(2)1
Avg Revenue beat(2)383.41%
Min Revenue beat(2)-23.41%
Max Revenue beat(2)790.23%
Revenue beat(4)1
Avg Revenue beat(4)169.32%
Min Revenue beat(4)-50.74%
Max Revenue beat(4)790.23%
Revenue beat(8)2
Avg Revenue beat(8)84.01%
Revenue beat(12)5
Avg Revenue beat(12)192.38%
Revenue beat(16)9
Avg Revenue beat(16)163.37%
PT rev (1m)3.47%
PT rev (3m)6.18%
EPS NQ rev (1m)5.88%
EPS NQ rev (3m)6.05%
EPS NY rev (1m)1.9%
EPS NY rev (3m)1.38%
Revenue NQ rev (1m)-21.62%
Revenue NQ rev (3m)-27.26%
Revenue NY rev (1m)0.83%
Revenue NY rev (3m)0.49%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 18.34
P/FCF N/A
P/OCF N/A
P/B 2.07
P/tB 2.07
EV/EBITDA N/A
EPS(TTM)-3.44
EYN/A
EPS(NY)-4.67
Fwd EYN/A
FCF(TTM)-3.53
FCFYN/A
OCF(TTM)-3.39
OCFYN/A
SpS1.37
BVpS12.16
TBVpS12.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -5.4%
ROE -6.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-16.2%
ROA(5y)-19.06%
ROE(3y)-23.77%
ROE(5y)-31.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 67.04%
Cap/Sales 10.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.09
Quick Ratio 13.09
Altman-Z 5.08
F-Score5
WACC8.91%
ROIC/WACCN/A
Cap/Depr(3y)92.13%
Cap/Depr(5y)250.13%
Cap/Sales(3y)11.24%
Cap/Sales(5y)40.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.55%
EPS Next Y-35.55%
EPS Next 2Y-17.14%
EPS Next 3Y-8.39%
EPS Next 5Y8.59%
Revenue 1Y (TTM)120.01%
Revenue growth 3Y31.88%
Revenue growth 5Y487.3%
Sales Q2Q%279.52%
Revenue Next Year23.62%
Revenue Next 2Y29.57%
Revenue Next 3Y51.98%
Revenue Next 5Y83.72%
EBIT growth 1Y7.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1.2%
EBIT Next 3Y5.41%
EBIT Next 5Y9.92%
FCF growth 1Y-1.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.62%
OCF growth 3YN/A
OCF growth 5YN/A

BEAM THERAPEUTICS INC / BEAM FAQ

What is the ChartMill fundamental rating of BEAM THERAPEUTICS INC (BEAM) stock?

ChartMill assigns a fundamental rating of 4 / 10 to BEAM.


Can you provide the valuation status for BEAM THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to BEAM THERAPEUTICS INC (BEAM). This can be considered as Overvalued.


Can you provide the profitability details for BEAM THERAPEUTICS INC?

BEAM THERAPEUTICS INC (BEAM) has a profitability rating of 2 / 10.


How financially healthy is BEAM THERAPEUTICS INC?

The financial health rating of BEAM THERAPEUTICS INC (BEAM) is 8 / 10.


What is the earnings growth outlook for BEAM THERAPEUTICS INC?

The Earnings per Share (EPS) of BEAM THERAPEUTICS INC (BEAM) is expected to decline by -35.55% in the next year.